Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson’s disease?

The adenosine A2A receptor is a major target of caffeine, the most widely used psychoactive substance worldwide. Large epidemiological studies have long shown caffeine consumption is a strong inverse predictor of Parkinson’s disease (PD). In this review, we first examine the epidemiology of caffeine use vis-à-vis PD and follow this by looking at the evidence for adenosine A2A receptor antagonists as potential neuroprotective agents. There is a wealth of accumulating biological, epidemiological and clinical evidence to support the further investigation of selective adenosine A2A antagonists, as well as caffeine, as promising candidate therapeutics to fill the unmet need for disease modification of PD.

• Publication year

  2020

• Venue

  Parkinsonism & Related Disorders

• Publication date

  2020-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.parkreldis.2020.10.024PMID 33349580PMCID 8102090
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Isradipine Versus Placebo in Early Parkinson Disease

  2020cited by this paper
• Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson’s Disease in the Harvard Biomarkers Study

  2020cited by this paper
• Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers

  2020cited by this paper
• Remote Administration of the MDS-UPDRS in the Time of COVID-19 and Beyond

  2020cited by this paper
• Age at Onset of Parkinson’s Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations

  2020cited by this paper
• The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis

  2020cited by this paper
• Effects of regular and decaffeinated roasted coffee (Coffea arabica and Coffea canephora) extracts and bioactive compounds on in vitro probiotic bacterial growth.

  2020cited by this paper
• The Therapeutic Implications of Tea Polyphenols against Dopamine (DA) Neuron Degeneration in Parkinson’s Disease (PD)

  2019cited by this paper
• The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease

  2019cited by this paper
• Enhanced ATP release and CD73‐mediated adenosine formation sustain adenosine A2A receptor over‐activation in a rat model of Parkinson's disease

  2019cited by this paper
• CD73-derived adenosine controls inflammation and neurodegeneration by modulating dopamine signalling

  2019cited by this paper
• A roadmap for implementation of patient‐centered digital outcome measures in Parkinson's disease obtained using mobile health technologies

  2019cited by this paper
• Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk

  2018cited by this paper
• Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB

  2018cited by this paper
• Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson's disease.

  2018cited by this paper
• Chronic Caffeine Treatment Protects Against α-Synucleinopathy by Reestablishing Autophagy Activity in the Mouse Striatum

  2018cited by this paper
• Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease.

  2018cited by this paper
• Selective A2A receptors blockade reduces degeneration of substantia nigra dopamine neurons in a rotenone-induced rat model of Parkinson's disease: A histological study.

  2017cited by this paper
• Caffeine as symptomatic treatment for Parkinson disease (Café-PD)

  2017cited by this paper
• Differences in Parkinson’s Disease Risk with Caffeine Intake and Postmenopausal Hormone Use

  2017cited by this paper
• α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies

  2017cited by this paper
• The effect of istradefylline for Parkinson’s disease: A meta-analysis

  2017cited by this paper
• Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease

  2017cited by this paper
• Neuroprotective effects of caffeine in MPTP model of Parkinson's disease: A (13)C NMR study.

  2016cited by this paper
• Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy.

  2016cited by this paper
• Influence of caffeine on 3,4‐methylenedioxymethamphetamine‐induced dopaminergic neuron degeneration and neuroinflammation is age‐dependent

  2016cited by this paper
• Dose-dependent neuroprotective effect of caffeine on a rotenone-induced rat model of parkinsonism: A histological study.

  2016cited by this paper
• A2A adenosine receptor deletion is protective in a mouse model of Tauopathy

  2016cited by this paper
• Non-Neuronal Cells Are Required to Mediate the Effects of Neuroinflammation: Results from a Neuron-Enriched Culture System

  2016cited by this paper
• Caffeine consumption and the 4-year progression of de novo Parkinson's disease.

  2016cited by this paper
• Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.

  2016cited by this paper
• Activation of Adenosine 2A receptor inhibits neutrophil apoptosis in an autophagy-dependent manner in mice with systemic inflammatory response syndrome

  2016cited by this paper
• Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2

  2016cited by this paper
• Autophagy and Alpha‐Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies

  2016cited by this paper
• The epidemiology of Parkinson's disease: risk factors and prevention.

  2016cited by this paper
• Differential effect of caffeine intake in subjects with genetic susceptibility to Parkinson’s Disease

  2015cited by this paper
• Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine

  2015cited by this paper
• Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.

  2015cited by this paper
• Coffee consumption and risk of levodopa‐induced dyskinesia in Parkinson's disease: The FRAGAMP study

  2015cited by this paper
• Parkinson's disease

  2015cited by this paper
• Adenosine A2A Receptors Modulate &agr;‐Synuclein Aggregation and Toxicity

  2015cited by this paper
• Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b.

  2014cited by this paper
• Caffeine stimulates hepatic lipid metabolism by the autophagy‐lysosomal pathway in mice

  2014cited by this paper
• Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment

  2014cited by this paper
• Brain Injection of α-Synuclein Induces Multiple Proteinopathies, Gliosis, and a Neuronal Injury Marker

  2014cited by this paper
• Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.

  2014cited by this paper
• A cup of coffee a day keeps dyskinesia away?

  2013influential reference
• Caffeine consumption and risk of dyskinesia in CALM‐PD

  2013cited by this paper
• Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely.

  2013cited by this paper
• Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia

  2013cited by this paper
• Kinetic Modeling, Test–Retest, and Dosimetry of 123I-MNI-420 in Humans

  2013cited by this paper
• The many faces of α-synuclein: from structure and toxicity to therapeutic target

  2012cited by this paper
• Caffeine intake, smoking, and risk of Parkinson disease in men and women.

  2012cited by this paper
• Caffeine and risk of Parkinson's disease in a large cohort of men and women

  2012cited by this paper
• Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.

  2012cited by this paper
• Protein degradation pathways in Parkinson’s disease: curse or blessing

  2012cited by this paper
• α-Synuclein and Neuronal Cell Death

  2012cited by this paper
• Adenosine A2A receptor gene disruption protects in an α‐synuclein model of Parkinson's disease

  2012cited by this paper
• Caffeine for treatment of Parkinson disease

  2012cited by this paper
• Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice

  2012cited by this paper
• Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion.

  2012cited by this paper
• Hypoxia and inflammation.

  2011cited by this paper
• Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.

  2011cited by this paper
• Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients

  2011cited by this paper
• Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.

  2011cited by this paper
• An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson’s disease

  2011cited by this paper
• Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

  2011cited by this paper
• Gastrodia elata prevents huntingtin aggregations through activation of the adenosine A₂A receptor and ubiquitin proteasome system.

  2011cited by this paper
• Caffeine potentiates methamphetamine-induced toxicity both in vitro and in vivo.

  2011cited by this paper
• Adenosine and ATP receptors in the brain.

  2011cited by this paper
• Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease

  2011cited by this paper
• An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers

  2010cited by this paper
• Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

  2010cited by this paper
• Alpha-synuclein stimulation of astrocytes

  2010cited by this paper
• Caffeine Exposure and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis of Observational Studiess

  2010cited by this paper
• Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women.

  2010cited by this paper
• Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice.

  2010cited by this paper
• Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.

  2010cited by this paper
• Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.

  2010cited by this paper
• Decaffeinated Coffee and Nicotine-Free Tobacco Provide Neuroprotection in Drosophila Models of Parkinson's Disease through an NRF2-Dependent Mechanism

  2010cited by this paper
• Local Glutamate Level Dictates Adenosine A2A Receptor Regulation of Neuroinflammation and Traumatic Brain Injury

  2010cited by this paper
• Adenosine signaling and function in glial cells

  2010cited by this paper
• A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity.

  2009cited by this paper
• The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.

  2009cited by this paper
• The delayed-start study design.

  2009cited by this paper
• A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

  2009cited by this paper
• A Critical Role of the Adenosine A2A Receptor in Extrastriatal Neurons in Modulating Psychomotor Activity as Revealed by Opposite Phenotypes of Striatum and Forebrain A2A Receptor Knock-Outs

  2008cited by this paper
• Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke.

  2008cited by this paper
• Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

  2008cited by this paper
• Prospective study of coffee consumption and risk of Parkinson's disease

  2008cited by this paper
• Why have we failed to achieve neuroprotection in Parkinson's disease?

  2008cited by this paper
• Caffeine and Progression of Parkinson Disease

  2008cited by this paper
• Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses.

  2008cited by this paper
• Adenosine, an endogenous distress signal, modulates tissue damage and repair

  2007cited by this paper
• Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers

  2007cited by this paper
• Adenosine receptors: therapeutic aspects for inflammatory and immune diseases

  2006cited by this paper
• Forebrain Adenosine A2A Receptors Contribute to l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Hemiparkinsonian Mice

  2006cited by this paper
• Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease

  2006cited by this paper
• Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.

  2005cited by this paper
• KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse.

  2005cited by this paper

• Maladie de Parkinson : physiopathologie, critères diagnostiques et signes cliniques

  2026cites this paper
• Selective antagonism of adenosine A2A receptor reduces hypobaric hypoxia-induced neuroinflammation by inhibiting cGAS-STING pathway

  2026cites this paper
• [Epidemiology of Parkinson's disease].

  2025cites this paper
• A Review of the Recent Advances in the Pharmacological Management of Parkinson’s Disease

  2025cites this paper
• Caffeine in Aging Brains: Cognitive Enhancement, Neurodegeneration, and Emerging Concerns About Addiction

  2025cites this paper
• The gut–brain axis in early Parkinson’s disease: from prodrome to prevention

  2025cites this paper
• Exploring Risk and Protective Factors in Parkinson’s Disease

  2025cites this paper
• Discovery of novel A2AR antagonist via 3D-QSAR pharmacophore modeling: neuroprotective effects in 6-OHDA-induced SH-SY5Y cells and haloperidol-induced Parkinsonism in C57 bl/6 mice

  2025cites this paper
• From Clinical to Basic Research: The Neuroprotective Effects and Mechanisms of Caffeine

  2025cites this paper
• Role of Reactive Astrocytes and Microglia: Wnt/β-Catenin Signaling in Neuroprotection and Repair in Parkinson’s Disease

  2025cites this paper
• A Review of the Protective Effects of Alkaloids Against Alpha-synuclein toxicity in Parkinson's disease.

  2024cites this paper
• Adenosine and Cortical Plasticity

  2024cites this paper
• Dietary Caffeine and Brain Dopaminergic Function in Parkinson Disease

  2024cites this paper
• Potential Correlation between Tea Intake and the Risk of Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study

  2024cites this paper
• Update: Protective and risk factors for Parkinson disease.

  2024cites this paper
• Caffeine consumption outcomes on amyotrophic lateral sclerosis disease progression and cognition.

  2024influential citation
• Coffee and multiple sclerosis (MS).

  2024cites this paper
• Microbiome-based therapies for Parkinson’s disease

  2024cites this paper
• Assessment of the Potential Toxic Consequences of Energy Drinks on the Brain Tissue of Maternal Wister Rats Throughout Gestation and Lactation

  2024cites this paper
• Glutathione S-transferase: A keystone in Parkinson's disease pathogenesis and therapy.

  2024cites this paper
• Drugs targeting adenosine signaling pathways: A current view.

  2023cites this paper
• Does dietary intake of caffeine have an effect on transient global amnesia?

  2023cites this paper
• Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease.

  2022cites this paper
• What to Test in Parkinson Disease Prevention Trials?

  2022influential citation
• The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic

  2022cites this paper
• Habitual Coffee Consumption Alters Attention and Memory in Older Adults: Significance of Intellectual Workload

  2022cites this paper
• Life style and Parkinson’s disease

  2022cites this paper
• Dietary sources, health benefits, and risks of caffeine

  2022cites this paper
• The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease

  2022cites this paper
• How Are Adenosine and Adenosine A2A Receptors Involved in the Pathophysiology of Amyotrophic Lateral Sclerosis?

  2021cites this paper
• Koffein, Schokolade und Adenosin A2A Rezeptorantagonisten in der Behandlung des Parkinson Syndroms

  2021influential citation
• Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease

  2021cites this paper
• Selected Literature Watch

  2021cites this paper
• A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases.

  2021cites this paper
• Adenosin A 2A Rezeptorantagonisten als Therapieoption beim idiopathischen Parkinson-Syndrom?

  2021cites this paper